Table 3.

Linear regression analysis of EFV percentage decrease and studied factors after six months of dapagliflozin.

Coefficients for EFV Decrease (%).
Baseline Independent Variables	Unstandardized Coefficients		Standardized Coefficients	t	p
	B	Std. Error	Beta
Age	−0.27	0.45	−0.09	−0.61	0.54
Diabetes duration	0.08	0.88	0.01	0.09	0.93
Weight	−0.07	0.29	−0.04	−0.26	0.79
BMI	−0.29	0.97	−0.04	−0.30	0.76
Waist	−0.58	0.40	−0.20	−1.45	0.15
TC	0.10	0.08	0.19	1.35	0.18
TG	0.04	0.03	0.22	1.55	0.12
HDLc	0.41	0.38	−0.15	−1.07	0.28
LDLc	0.14	0.10	0.20	1.40	0.16
Uric acid	−5.90	4	−0.22	−1.47	0.14
CRR	4.35	2.13	0.28	2.04	0.04 *
AIP	28.54	13.78	0.29	2.07	0.04 *
Conicity index	−119.26	55.2	−0.29	−2.16	0.03 *
TyG index	27.38	11.35	0.33	2.41	0.02 *
VAI
Women	0.89	1.95	0.11	0.46	0.65
Men	1.70	1.32	0.23	1.29	0.20
Glycemia	0.10	0.07	0.22	1.59	0.11
HbA1c	3.96	3.86	0.14	1.03	0.31
EFV	1.38	0.18	0.73	7.50	<0.001 *
L4VFV	−0.36	0.15	−0.32	−2.38	0.02 *
L4VFV decrease (%)	−0.04	0.02	−0.31	−2.31	0.02 *
Left atrium volume	−0.97	0.32	−0.40	−3.08	0.003 *
Right ventricle diameter	−48.72	22.90	−0.33	−2.13	0.04 *
CAP	0.05	0.10	0.07	0.48	0.63
Fibroscan	0.04	0.70	0.01	0.05	0.95

* The correlations are statistically significant. BMI = body mass index; Waist = abdominal circumference; TC = total cholesterol; TG = triglyceride; HDLc = high-density lipid cholesterol; LDLc = low-density lipid cholesterol; HbA1c = glycated hemoglobin; EFV = epicardial fat volume; L4VFV = visceral fat volume at the 4th vertebrae; AIP = atherogenic index plasma; CRR = cardiac risk ratio; AC = atherogenic coefficient; TyG = product of triglycerides and glucose; VAI = visceral adiposity index; CAP = controlled attenuation parameter; Fibroscan = liver stiffness score.